{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T13:31:31Z","timestamp":1794317491215,"version":"4.9.0"},"reference-count":9,"publisher":"American Society of Hematology","issue":"18","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,9,24]]},"DOI":"10.1182\/bloodadvances.2024013813","type":"journal-article","created":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T15:31:14Z","timestamp":1727191874000},"page":"4977-4978","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":6,"title":["Defining infection risk of bispecific antibodies for myeloma"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4271-7443","authenticated-orcid":false,"given":"Sarah P.","family":"Hammond","sequence":"first","affiliation":[{"name":"Divisions of Infectious Diseases and Hematology\/Oncology, Massachusetts General Hospital; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"18","key":"2024092415310868400_bib1","doi-asserted-by":"crossref","first-page":"4979","DOI":"10.1182\/bloodadvances.2024013461","article-title":"Proposal for harmonizing the reporting of infections during treatment with bispecific antibodies in multiple myeloma","volume":"8","author":"Ludwig","year":"2024","journal-title":"Blood Adv"},{"issue":"6","key":"2024092415310868400_bib2","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1002\/cncr.35107","article-title":"Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed\/refractory multiple myeloma in the MajesTEC-1 study","volume":"130","author":"Nooka","year":"2024","journal-title":"Cancer"},{"issue":"10","key":"2024092415310868400_bib3","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1200\/JCO.22.02197","article-title":"Acknowledging infection risk in bispecific antibody trials in the treatment of multiple myeloma","volume":"41","author":"Cliff","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"2024092415310868400_bib4","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41408-023-00879-7","article-title":"Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel","volume":"13","author":"Raje","year":"2023","journal-title":"Blood Cancer J"},{"issue":"5","key":"2024092415310868400_bib5","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/bjh.18909","article-title":"Recommendations on prevention of infections during chimeric antigen receptor T-cell and bispecific antibody therapy in multiple myeloma","volume":"203","author":"Mohan","year":"2023","journal-title":"Br J Haematol"},{"issue":"13","key":"2024092415310868400_bib6","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1182\/bloodadvances.2022009435","article-title":"Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis","volume":"7","author":"Mazahreh","year":"2023","journal-title":"Blood Adv"},{"issue":"6","key":"2024092415310868400_bib7","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.cmi.2024.02.023","article-title":"Characteristics and incidence of infections in patients with multiple myeloma treated by bispecific antibodies: a national retrospective study","volume":"30","author":"Jourdes","year":"2024","journal-title":"Clin Microbiol Infect"},{"issue":"6","key":"2024092415310868400_bib8","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/2643-3230.BCD-23-0049","article-title":"IVIg use associated with ten-fold reduction of serious infections in multiple myeloma patients treated with anti-BCMA bispecific antibodies","volume":"4","author":"Lancman","year":"2023","journal-title":"Blood Cancer Discov"},{"issue":"1","key":"2024092415310868400_bib9","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1182\/bloodadvances.2023011658","article-title":"Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementation","volume":"8","author":"Freriches","year":"2024","journal-title":"Blood Adv"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/18\/4977\/2243819\/blooda_adv-2024-013813-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/18\/4977\/2243819\/blooda_adv-2024-013813-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T15:31:16Z","timestamp":1727191876000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/18\/4977\/517932\/Defining-infection-risk-of-bispecific-antibodies"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,24]]},"references-count":9,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2024,9,24]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024013813","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,24]]}}}